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Neurologists and stroke physicians will be familiar with atrial fibrillation as a major cause of ischaemic 2 
stroke, and the role of anticoagulation in preventing cardioembolic stroke. However, making decisions 3 
about anticoagulation for individual patients remains a difficult area of clinical practice, in which the 4 
serious risks of ischaemic stroke and major bleeding, particularly intracranial haemorrhage, must be 5 
carefully balanced. Atrial fibrillation is an interdisciplinary condition, in which collaboration with 6 
colleagues in cardiology and haematology is essential. Recent advances in the field, most notably the 7 
now-widespread availability of direct oral anticoagulants, have brought opportunities to improve 8 
stroke care while posing new challenges. This article gives an overview of the contemporary diagnosis 9 
and management of atrial fibrillation, and the associated evidence base. Where uncertainty exists, we 10 
describe our own approach to these areas, while highlighting ongoing research which is likely to guide 11 


















1. INTRODUCTION 1 
Atrial fibrillation (AF) affects 2% of the UK population over 45 years old, and 4% of those over 65 [1]. 2 
It causes at least one-fifth of ischaemic strokes [2], and is one of the strongest individual stroke risk 3 
factors [3]. Most AF patients presenting to a neurologist will do so following an ischaemic stroke or 4 
TIA, but AF may also be found incidentally. The mainstay of stroke prevention in AF is anticoagulation, 5 
which is highly effective in preventing disabling ischaemic cardioembolic stroke, but can cause serious 6 
complications, most notably intracranial haemorrhage, which is unpredictable and often fatal or 7 
disabling. Treatment decisions in AF are therefore often complex and associated with important risks 8 
that are difficult to quantify. Indeed, balancing treatments to reduce ischaemic (vaso-occlusive) events 9 
while minimising the risk of intracranial bleeding is a central challenge of stroke medicine. Here, we 10 
aim to provide an overview and practical approach to the common issues likely to be encountered by 11 
neurologists in relation to atrial fibrillation, while highlighting some important uncertainties.  12 
2. ATRIAL FIBRILLATION AS A RISK FACTOR FOR ISCHAEMIC STROKE 13 
The first description of atrial thromboembolism came, perhaps surprisingly, from a neurologist: in 14 
1875, William Gowers described simultaneous emboli in the brain and retina, spleen and kidneys, 15 
concluding that they had all originated in the left atrial appendage, which contained clots [4]. In the 16 
early 20th century autopsy studies linked mitral stenosis, AF and intracardiac thrombus formation, and 17 
so identified the contribution of AF to stroke risk [5]. The connection between “non-valvular” AF and 18 
stroke was then consolidated by Miller Fisher and Adams in 1951 [6]. The risk was quantified by Wolf 19 
and colleagues in 1978, using epidemiological data from the Framingham study: valvular and non-20 
valvular AF increased ischaemic stroke risk 17-fold and five-fold respectively overall [7]. Much effort 21 
has since aimed to estimate ischaemic stroke risk in individual patients, producing the risk scoring 22 
systems which are the mainstay of current guidelines.  23 
Paroxysmal, persistent, and permanent AF 24 
An initial consideration in estimating ischaemic stroke risk is whether all types of AF – paroxysmal, 25 
persistent, and permanent – are equivalent. No current national or international guideline makes a 26 
distinction [8–10], based largely on observational longitudinal data from the Stroke Prevention in 27 
Atrial Fibrillation studies in the 1980s and 90s, which showed no difference in annual ischaemic stroke 28 
rate in aspirin-treated patients in paroxysmal versus persistent or permanent AF (3.2% vs. 3.3%) [11]. 29 
Conflictingly, a more recent retrospective analysis of patients enrolled into the ACTIVE-A and 30 
AVERROES studies receiving aspirin monotherapy suggests that persistent and permanent AF might 31 
carry a higher risk than paroxysmal AF (3.0%, 4.2%, and 2.1%/year, respectively) [12]. These results 32 
 4 
might be more applicable to contemporary practice, given advances in the management of other 1 
cardiovascular risk factors. However, in practice, a quarter of patients with paroxysmal AF will progress 2 
to persistent or permanent AF within five years, and a third within ten years [13]. In our view it is 3 
therefore reasonable to treat paroxysmal, persistent, and permanent AF in the same way. 4 
Risk scores: CHADS2 and CHA2DS2VASc 5 
The first widely-adopted AF stroke risk score was the CHADS2 score (table 1), which included risk 6 
factors identified by the Atrial Fibrillation Investigators (AFI) [14] and the Stroke Prevention and Atrial 7 
Fibrillation (SPAF) investigators [15], and was validated in an independent cohort  of 1,733 Medicare 8 
beneficiaries [16]. Limitations included the exclusion of patients under 65, limiting widespread 9 
applicability, and the inclusion of a low proportion of high-risk (CHADS2 >4) patients, giving rise to 10 
wide confidence intervals for ischaemic stroke risk in higher-scoring patients (table 2). Importantly, 11 
around a quarter of patients in the validation cohort had an “intermediate risk” CHADS2 score of 1, a 12 
proportion that increased to 60% in subsequent studies [17]. This is problematic because in this large 13 
patient population the treating physician would need to make a judgement between doing nothing, 14 
giving aspirin (no longer advised under European Society of Cardiology guidelines) or recommending 15 
anticoagulation. 16 
Table 1: CHADS2 and CHA2DS2VASc risk scores 17 
CHADS2 CHA2DS2VASc 
Risk factor Score Risk factor Score 
Congestive 
heart failure 
1 Congestive heart failure 1 
Hypertension 1 Hypertension 1 
Age ≥75 1 Age ≥75 2 
Diabetes 1 Diabetes 1 
Stroke/TIA 2 Stroke/TIA 2 
  Vascular (MI, PAD, aortic plaque) 1 
  Age ≥65 (<75) 1 
  Sex category (female) 1 
Score <1: Low risk; 1: intermediate risk; >1 high risk* 
 
* Note that in ESC 2016 guidelines that female gender alone does not score 1 unless in 
presence of an additional risk factor 
 5 









The CHA2DS2VASc system was developed in response, by including additional risk factors and a lower 10 
age threshold of 65 years while further weighting ages over 75 years (table 1) [17]. Validated on the 11 
Euro Heart Survey on AF population in 1,084 patients not taking anticoagulants at baseline, the 12 
CHA2DS2VASc low-risk category had a very low incidence of thromboembolic events (none in the 13 
initial validation cohort, table 3), and the number of patients categorised as being at intermediate risk 14 
(14.9%) was lower than with CHADS2 (table 3). There remain limitations of this revised score: a 15 
number of important ischaemic stroke risk factors are not included – notably left atrial remodelling 16 
from any aetiology (detectable on echocardiography), chronic kidney disease (particularly those with 17 
CKD 3B or greater (eGFR <45ml/min/1.73m2)), obstructive sleep apnoea, circulating cardiac 18 
biomarkers (review [18]), or brain biomarkers of cerebrovascular disease [19]. Scoring systems that 19 
incorporate one or more of these factors have been developed and are in the process of validation. 20 
For example, the ABC score combines age, cardiac biomarkers (NT-proBNP and Troponin I), and clinical 21 
history of stroke or TIA, outperforming CHA2DS2VASc in its derivation and external validation cohorts, 22 
with c-statistics of 0.68 and 0.66 vs. 0.62 and 0.58 respectively [20]. However, whether such scores 23 
offer a significant advantage in clinical practice over the simple and cheap CHA2DS2VASc score 24 















stroke rate (95% CI) 
0 120 6.9 2 1.9 (1.2-3.0) 
1 463 26.7 17 2.8 (2.0-3.8) 
2 523 30.2 23 4.0 (3.1-5.1) 
3 337 19.4 25 5.9 (4.6-7.3) 
4 220 12.7 19 8.5 (6.3-11.1) 
5 65 3.8 6 12.5 (8.2-17.5) 
6 5 0.3 2 18.2 (10.5-27.4) 
 6 
Table 3: CHA2DS2VASc data table – adapted from [17] 1 














for aspirin use 
0 103 9.5 0 0 (0-0) 0 
1 162 14.9 1 0.6 (0.0-3.4) 0.7 
2 184 17.0 3 1.6 (0.3-4.7) 1.9 
3 203 18.7 8 3.9 (1.7-7.6) 4.7 
4 208 19.2 4 1.9 (0.5-4.9) 2.3 
5 95 8.8 3 3.2 (0.7-9.0) 3.9 
6 57 5.3 2 3.6 (0.4-12.3) 4.5 
7 25 2.3 2 8.0 (1.0-26.0) 10.1 
8 9 0.8 1 11.1 (0.3-48.3) 14.2 
9 1 0.1 1 100 (2.5-100) 100 
 2 
Risk scores: more than stroke risk? 3 
An interesting point to note is that the CHADS and CHA2DS2VASc scores are essentially summaries of 4 
cardiovascular risk factors that portend endothelial and myocardial dysfunction, and so do not only 5 
predict ischaemic stroke risk. Even in patients without AF, both scores correlate with measures of 6 
general vascular dysfunction and perform moderately well in predicting ischaemic stroke, myocardial 7 
infarction and cardiovascular death [21]. Moreover, in patients admitted with an acute coronary 8 
syndrome, the CHADS2 and CHA2DS2VASc scores also predict ischaemic stroke independently of an 9 
antecedent diagnosis of AF [22].  Both scores also predict new onset of AF, with c-statistics of 0.72 and 10 
0.74 respectively [23]. Therefore, in those with cryptogenic stroke, a high CHA2DS2VASc score should 11 
perhaps prompt a more aggressive rhythm monitoring strategy in those patients in whom initial 12 
rhythm monitoring has not made an AF diagnosis. 13 
3. DIAGNOSIS OF AF AFTER STROKE  14 
In the UK,  15–20% of acute ischaemic stroke patients have known atrial fibrillation at the time of 15 
stroke [24,25]. Standard guideline-based investigations for AF in the remainder, if potentially eligible 16 
for anticoagulation, would comprise a routine ECG on admission, inpatient telemetry lasting 12–24hrs, 17 
and, in the absence of a definite alternative mechanism, further outpatient monitoring, usually for 1–18 
7 days [26–28]. A further ~20% of patients will be diagnosed with AF by this approach [2]. Three major 19 
 7 
randomised controlled trials have examined what further monitoring should be undertaken in patients 1 
with cryptogenic stroke (i.e. those with no alternative cause found after standard investigations, 2 
including imaging of the extracranial arteries): CRYSTAL-AF, EMBRACE, and FIND AFRANDOMISED [29–31]. 3 
The results, summarised in Table 4, showed significantly higher detection rates with more intensive 4 
rhythm monitoring strategies than with standard care. Higher use of oral anticoagulation resulted, 5 
though these studies were not powered to show reduced recurrent stroke risk. In CRYSTAL-AF, the 6 
detection rate continued to rise past one year, reaching 30% at 3 years [32]. Although this might 7 
partially represent incident AF unrelated to the original stroke, this finding would still generally justify 8 
anticoagulation in an ischaemic stroke patient.  9 
10 
 8 
Table 4: Key trials of prolonged ECG monitoring after ischaemic stroke; the results show the rate of AF 1 
detection in the intervention (I) and control (C) arms of the studies. 2 
 CRYSTAL-AF [29,32] EMBRACE [30] FIND AFRANDOMISED 
[31] 
Population Cryptogenic stroke 
within 90 days; >40yrs; 
negative vascular 
imaging, TOE, 
thrombophilia screen + 
>24hrs ECG monitoring; 
n=441 
Cryptogenic stroke 
within 6 months; 
>55yrs; negative 
vascular imaging, 
echo, >24hrs ECG 
monitoring 
Cryptogenic stroke 
within 7 days; 
>60yrs; negative 
vascular imaging 
and admission ECG 








months and six 
months 
Control Routine care (ad hoc 
ECG and Holter 
monitoring) 
Additional 24hr Holter 
monitoring 
At least 24hrs 
telemetry (mean 
73hrs) +/- 24hrs 
Holter monitoring 
Outcome Detection rate AF 
episode >2mins (I) or 
>30s (C)  
Detection rate AF 
episode >30s 
Detection rate AF 
episode >30s 
Results Follow up 
(months) 
I C I C I C 
1 3.7% 3.7% 16.1% 3.2%   
6 8.9%    13.5% 4.5% 
12 12.4%      
24 21.1%      






Which patients should have prolonged monitoring? 1 
Risk factors and biomarkers of AF could theoretically help select patients for prolonged monitoring.  2 
However, many patient-related risk factors for AF, such as age and hypertension, are poorly-3 
discriminating, also being risk factors for atherosclerosis [33]. Heart failure and mitral stenosis might 4 
be more specific [34], and the recently-developed HAVOC risk score, which weights congestive heart 5 
failure heavily, has shown potential for triaging cryptogenic stroke patients into low, medium and 6 
high-risk categories for AF detection [35].  ECG biomarkers including PR prolongation and atrial 7 
premature beat count are also being developed [36,37].  8 
Clinical and radiological features might also help identify patients likely to have AF. Large cardiac fibrin-9 
rich thrombi tend to travel in medium calibre high-flow vessels, leading to proximal arterial occlusion 10 
and a large infarct, or fragmentation and distal embolization into terminal cortical branches. 11 
Consequently, the features of cardioembolic stroke include higher clinical severity, more cortical 12 
symptoms and signs, and certain radiological patterns (figure 1), including whole-territory infarction, 13 
wedge-shaped infarcts extending into the cortex, striatocapsular infarction (from transient M1 14 
occlusion), isolated posterior cerebral artery infarction causing hemianopia, scattered distal infarcts 15 
within an arterial territory or external borderzone, and multi-territory bihemispheric or anterior and 16 
posterior circulation infarcts [38]. Haemorrhagic transformation has also been suggested to be 17 
characteristic of cardiac embolism, since cardiac, “red” (fibrin-rich) thrombi are more liable to re-18 
perfuse and consequently have associated haemorrhage within the infarct. However, none of these 19 
findings are wholly reliable: even small subcortical infarction has been described in the presence of a 20 
definite embolic mechanism [39], and a recent meta-analysis showed that the AF detection rate at 21 
seven days after ischaemic stroke is similar whether the stroke is classified clinico-radiologically as due 22 
to small or large vessel occlusion [40]. Importantly, high detection rates in the prolonged monitoring 23 
trials were obtained in relatively unselected cryptogenic stroke patients. Therefore, until a biomarker-24 
based approach is validated, we advocate prolonged monitoring in all cryptogenic stroke patients. 25 
Monitoring techniques 26 
The optimal techniques for ECG monitoring are uncertain, with a lack of head-to-head trials and recent 27 
rapid advances in device design. In most departments, first-line non-invasive AF detection remains via 28 
Holter monitoring, developed in 1962 and limited by relatively short recording duration, bulky design, 29 
an inability to use while showering, and delays in reporting. Newer hand-held patient-activated 30 
devices such as Kardia and Zenicor offer portability, cost-effectiveness and speed [41], but do not offer 31 
the continuous monitoring required to detect asymptomatic AF. Our preference is for newer patch-32 
monitoring devices, such as ZIO, Bardy or e-Patch, or lead monitoring via R-test or Apoplex (table 5, 33 
 10 
figure 2). These devices allow continuous monitoring for longer durations, a lightweight water-1 
resistant design, easy application in clinic by a nurse or doctor, and email reporting within 72 hours. 2 
  3 
 11 
Table 5: ECG monitoring devices  1 
 Patch monitors Standard lead monitors 
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of data  
N Y N Y N Y 
Recording 
duration 
7 days 5 days 14 days 1-72 
hours** 
 
1-7 days 16-32 days 
Time to 
report 
<72hrs <72 hours 48-72hrs <24hrs Locally 
dependent 
48hrs 
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VT, ectopics, 
pauses 











































to clinic and 
data uploaded 
for analysis 












































Email report Email report  
 
Option for 
data to be 
reviewed 
locally 





Email report  
 
Option for data 





Y N Y N Y N 
*Placement on sternum thought to improve AF detection compared to other patches but no head to head trials  2 
** We use the Apoplex device for in clinic monitoring, applied at start of clinic and removed after all tests are 3 
complete that day 4 
 5 
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After non-invasive monitoring, our practice is to proceed to prolonged monitoring via an implanted 1 
cardiac monitor in patients whose ischaemic stroke remains unexplained, with a high suspicion of 2 
cardiac embolism (e.g. non-lacunar, especially if due to cortical branch occlusion, or in multiple 3 
vascular territories, or with other radiological characteristics shown in figure 1), and in whom we 4 
would recommend anticoagulation if AF is found. Traditional catheter-inserted monitors have now 5 
been replaced by subcutaneous devices, inserted via a <1cm incision, which offer up to 3 years of 6 
continuous monitoring, MRI-compatibility, automated arrhythmia detection as well as a patient-7 
activated event alarm, and wireless data download. The Reveal LINQ monitor (figure 3) has recently 8 
been the subject of a NICE MedTech Innovation briefing [42]. Such systems are generally well-9 
tolerated, being small and lightweight, with a low rate of complications (in CRYSTAL-AF, the removal 10 
rate due to infection or erosion was 2.4%).  Whether their use translates into a reduced risk of stroke 11 
is being addressed by the LOOP trial, expected to report in 2020  [43]. 12 
Low-burden and implanted device-detected AF 13 
With the greater use of prolonged monitoring, an increasing number of patients will be found who 14 
have short and infrequent paroxysms of AF – that is, a low ‘AF burden’. The patients in the key clinical 15 
trials of anticoagulation and risk score development cohorts will largely have been diagnosed by short 16 
duration monitoring, and are therefore more likely to have had a high AF burden. Therefore, whether 17 
low-burden AF patients diagnosed through prolonged monitoring benefit similarly from 18 
anticoagulation is an important uncertainty. However, current national and international guidelines 19 
do not distinguish by AF burden, and our practice is to consider anticoagulation in any patient with 20 
proven AF of any duration. It is likely that AF burden increases over time, and the haemodynamic 21 
effects of irregular atrial contraction may not be the only mechanism of intracardiac thrombosis in AF 22 
[44]. Most studies correlating AF burden with stroke risk have been performed in patients with 23 
pacemakers or implanted cardioverter-defibrillators able to detect paroxysmal atrial tachycardias 24 
termed ‘atrial high rate episodes’ (AHREs). The results of these studies are inconsistent, finding 25 
ischaemic stroke risk to be increased variously by the presence of an AHRE >5 minutes, 6 minutes or 26 
24hrs, or by a  daily burden of 5.5hrs or more on at least one day during the monitoring period [45–27 
49]. AHREs correlate with AF detection on dedicated rhythm monitoring, but imperfectly; therefore, 28 
these results should not be extrapolated directly to patients with proven AF. Neurologists should 29 
however be aware that interrogation of an implanted cardiac device in a stroke patient may provide 30 
evidence of an increased risk of AF, and that two clinical trials (NOAH AFNET-6 and ARTESIA) are testing 31 
the benefit of anticoagulation in patients with AHREs lasting less than 24hrs [50,51]. In the meantime, 32 
a proposed approach for the management of AHREs, based on European Society of Cardiology 33 
guidance, is to consider anticoagulation for patients with a previous ischaemic stroke, or with an AHRE 34 
 13 
>24hrs and two or more non-gender risk factors in CHA2DS2VASc [8,52]. For other patients, an AHRE 1 
should prompt ECG monitoring, and consideration of anticoagulation if AF is then documented. 2 
Neurogenic AF 3 
A further complexity concerning AF diagnosed after stroke is that a proportion of this may be caused 4 
by abnormal autonomic drive, possibly related to insular brain injury [53], and inflammation, 5 
especially if detected in the acute phase. This ‘neurogenic’ AF could be a transient phenomenon and 6 
not require long-term anticoagulation, unlike ‘cardiogenic’ AF due to structural heart disease [54]. 7 
Although there is insufficient supporting evidence to change clinical practice, it has recently been 8 
reported that recurrent ischaemic stroke risk in patients diagnosed with AF after stroke is low 9 
compared to that of patients known to have AF prior to stroke, and similar to that observed in sinus 10 
rhythm [55]. Repeat rhythm monitoring, delayed by several months, might be of value in stratifying 11 
the longer-term risk in these patients. 12 
4. DECIDING ON ANTICOAGULATION 13 
In AF patients, oral anticoagulation with warfarin reduces the relative risk of ischaemic stroke by 14 
approximately two-thirds, regardless of absolute risk [56,57]; this means that those patients at highest 15 
absolute risk gain the most absolute benefit from anticoagulation. Direct oral anticoagulants (DOACs) 16 
offer similar protection against ischaemic stroke to vitamin K antagonists (warfarin) [58]. This benefit 17 
must be weighed against the risk of anticoagulation-associated haemorrhage, particularly 18 
intracerebral haemorrhage (ICH), which is rare (generally less than 1% per year in clinical trials) but 19 
incurs much higher morbidity and mortality than ischaemic stroke [59]. The trade-off between the 20 
reduced risk of ischaemic stroke and increased risk of ICH, weighted by severity, has been described 21 
as the ‘net clinical benefit’ of anticoagulation. Overall, using CHADS2 for risk stratification, a positive 22 
net clinical benefit is obtained for patients scoring 2 or more [60]. A subsequent analysis using 23 
CHA2DS2VASc, which is more accurate than CHADS2 in lower-risk patients, found a small net clinical 24 
benefit for patients with a score of 1 [61]. Female patients with a CHA2DS2VASc of 1 (that is, with no 25 
other risk factors beyond gender) have a very low risk of ischaemic stroke, comparable to that for men 26 
with CHA2DS2VASc of 0, and may not benefit from anticoagulation with warfarin [62]. The threshold 27 
for benefit with DOAC use has not been as fully studied, but modelling indicates this is likely to be 28 
lower, due to their substantially reduced risk of ICH [63]. In view of these data, the 2016 European 29 
Society of Cardiology guidelines suggest consideration of anticoagulation for any patient with AF and 30 
a single non-gender CHA2DS2VASc risk factor  [8], as do the 2018 guidelines of the American College 31 
of Chest Physicians (ACCP) [64]. The 2014 American Heart Association guidelines endorse 32 
anticoagulation for CHA2DS2VASc >1, but suggest no treatment, anticoagulation or aspirin for patients 33 
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with CHA2DS2VASc =1, though acknowledge a lack of evidence for aspirin in the prevention of 1 
cardioembolic stroke [65]. 2 
Having established that a patient has an appreciable ischaemic stroke risk and should be considered 3 
for anticoagulation, the next step is to assess bleeding risk. Ideally, it would be possible to calculate 4 
the net clinical benefit of anticoagulation for an individual. To this end, several bleeding risk scores 5 
have been generated, including HASBLED, HEMORR2HAGES, ATRIA and ORBIT.  These scores perform 6 
similarly and modestly, with c-statistics for major bleeding between 0.6 and 0.7 [66]. Limitations of 7 
risk scores include the use of risk factors which are dynamic and difficult to know prospectively or 8 
based on a single assessment (e.g. uncontrolled hypertension, labile INR), the use in some cases of 9 
variables not routinely measured in clinical practice (e.g. genetic data in HEMORR2HAGES), their 10 
derivation largely for warfarin-treated patients, and the use of a composite ‘major bleeding’ outcome 11 
measure which weights a two-unit transfusion equally to a disabling ICH. Notably, they perform less 12 
well for predicting intracranial haemorrhage specifically, the major bleeding risk relevant to 13 
anticoagulation decisions in atrial fibrillation, with c-statistics close to 0.5 [67]. Given this, a 14 
straightforward comparison of calculated ‘major bleeding’ and ischaemic stroke risks cannot currently 15 
be recommended. However, bleeding risk scores are useful to inform discussions with patients 16 
considering anticoagulation, and to identify patients requiring closer monitoring and aggressive 17 
treatment of modifiable bleeding risk factors.   Patients at particularly high risk of bleeding and stroke 18 
may be considered for non-pharmacological treatment, such as left atrial appendage occlusion.  19 
More precise estimation of bleeding risk (including intracranial haemorrhage) might be enabled 20 
through the use of MRI biomarkers including cerebral microbleeds (figure 4) [19]. The CROMIS-2 study 21 
included 1490 participants with recent ischaemic stroke or TIA and AF; the symptomatic intracranial 22 
haemorrhage rate in patients with cerebral microbleeds was 9.8 per 1000 patient-years (95% CI 4·0-23 
20·3) compared with 2.6 per 1000 patient-years (95% CI 1·1-5·4) in those without cerebral microbleeds 24 
(adjusted hazard ratio 3·67, 95% CI 1·27-10·60). Compared with the HAS-BLED score alone, models 25 
including cerebral microbleeds predicted symptomatic intracranial haemorrhage significantly better 26 
with a c-statistic of 0.74 (95% CI 0.60-0.88). Further data from large international collaborative studies 27 
are awaited to establish the value of cerebral microbleeds in predicting intracranial haemorrhage. 28 
Anticoagulation in the elderly 29 
Beyond bleeding risk scores, increasing age is sometimes seen as a contraindication to 30 
anticoagulation, particularly in those over 75 years, with antiplatelets sometimes used instead. Older 31 
patients are at the highest risk of stroke, so have the most to gain from treatment, and to lose if 32 
anticoagulation is needlessly withheld. The BAFTA study [68] showed warfarin to be superior to aspirin 33 
 15 
in stroke prevention in patients aged seventy-five or older (mean age 81.5 +/- 4.2yrs), with a relative 1 
risk of all-cause stroke of 0.48 in the warfarin arm. The risk of haemorrhagic complications did not vary 2 
significantly between the two groups, and was relatively low overall, with an annual risk of major 3 
haemorrhage of 1.9% with warfarin and 2.0% with aspirin (and 2.9% and 3.7% respectively in those 4 
>85yrs). The relative efficacy of warfarin in ischaemic stroke prevention is maintained despite 5 
increasing age, so a greater absolute benefit is derived in older, and so higher risk, patients, 6 
outweighing a slower increase in ICH risk. Overall, older patients seem to gain a greater net clinical 7 
benefit from anticoagulation [69]. Secondary analyses of three pivotal DOAC trials (ARISTOTOLE, 8 
ROCKET-AF and RE-LY) show that older patients benefit similarly to younger patients from DOACs 9 
[70,71], although the use of dabigatran at the higher dose of 150mg BD is associated with high rates 10 
of extracranial bleeding in those older than 80 years [72]. We therefore do not recommend any upper 11 
age cut-off for considering anticoagulation.  12 
Cognitive impairment, frailty, and falls 13 
These are common reasons for withholding anticoagulation, but this might be unjustified. The use of 14 
a DOAC potentially avoids much of the difficulty of warfarin monitoring in cognitively-impaired 15 
patients, but measuring adherence might be challenging unless a relative or carer is available to 16 
supervise use. Frailty, usually defined as a decline in physiological reserve across multiple systems 17 
leading to increased vulnerability to stressors, is independently associated with reduced prescription 18 
of anticoagulants [73], but the limited evidence available does not support this: in the ORBIT-AF 19 
registry of nearly 10,000 patients, of whom over 500 met AGS criteria for frailty, survival was improved 20 
by anticoagulation even in frail patients, and frailty did not independently predict an increased risk of 21 
major bleeding or stroke [74]. Falls are cited as a reason to withhold anticoagulation in over a quarter 22 
of untreated AF patients [75]. This is understandable: anticoagulation with warfarin triples the risk of 23 
subdural haemorrhage [76], thought often due to falls, and frequent falls quadruple the risk of 24 
traumatic ICH [77]. However, ICH after a single fall is rare, even in anticoagulated patients [78], and 25 
the risk of subdural haemorrhage in anticoagulated AF patients is very low compared to the risk of 26 
ischaemic stroke [76]. As a result, it has been estimated that an AF patient with an 6% annual 27 
ischaemic stroke risk would need to fall 295 times per year not to benefit from warfarin [79]. Although 28 
this figure will be lower for patients with a lower ischaemic stroke risk, the average elderly patient 29 
who falls does so only 1.8 times each year, and most patients who fall will have an elevated stroke risk 30 
because of their age and co-morbidities. Pragmatically, it is also not clear that being screened as ‘high 31 
falls risk’ or having fallen in the last year is associated with an increased risk of haemorrhage in 32 
anticoagulated patients [80,81]. Therefore, we do not recommend withholding anticoagulation in 33 
patients who fall, but do suggest a thorough assessment and modification of falls risk where possible. 34 
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5. STARTING AN ANTICOAGULANT 1 
Most AF patients will be offered a vitamin K antagonist (VKA; generally, warfarin), a direct thrombin 2 
inhibitor (dabigatran), or a factor Xa inhibitor (apixaban, rivaroxaban, edoxaban). The latter classes act 3 
directly on components of the common coagulation pathway, so are termed ‘direct oral 4 
anticoagulants’ (DOACs). Compared to warfarin, they have a rapid onset of action, without an initial 5 
procoagulant effect, a short half-life, few interactions with food and medication, and do not require 6 
dose titration or monitoring blood tests. Their characteristics are summarised in Table 6. In phase 7 
three trials, all were at least non-inferior to warfarin for the prevention of stroke and systemic 8 
embolism (SES), with about half the rate of intracranial haemorrhage [82–85]. This clinical trial data is 9 
strongly supported by data from observational studies in ‘real world’ populations [86]. Our practice, 10 
supported by European guidelines [8], is to recommend a DOAC to all patients without a specific 11 
indication for a VKA (e.g. a mechanical prosthetic heart valve or significant mitral stenosis [87]) (box 12 
1). We also generally prefer a VKA (or low molecular weight heparin) in patients with active 13 
malignancy, in whom fluctuations in renal function and body weight are common during treatment 14 
and disease course. However, a recent analysis of outcomes for patients in ENGAGE-AF-TIMI 48 15 
diagnosed with cancer during the trial found the benefit of edoxaban to be preserved, suggesting that 16 
the use of DOACs in these patients should be investigated further [88]. 17 
  18 
 17 
Table 6: Summary of oral anticoagulant properties 1 
 Apixaban Edoxaban Rivaroxaban Dabigatran Warfarin 




Indication Non-valvular AF + 1 of: 
 Ischaemic stroke/TIA 
 Age >75yrs 
 Symptomatic/congestive HF 
 DM 




Standard dose 5mg BD 60mg OD 20mg OD 150mg BD Dose-adjusted 
to INR 
Reduced dose 2.5mg BD 





(any of: CrCL 
<50ml/min, weight 
<60kg, concomitant 












Contraindications Clinically-significant bleeding or high risk of bleeding complication 
 CrCl 
<15ml/min 



































Pharmacokinetics T1/2: c. 12hrs 
27% renal excretion 
T1/2: 10-14hrs 
35% renal excretion 




80% renal excretion 







CYP3A4 + P-gp 
inhibitors2 
 




Reduce dose: Strong 
P-gp inhibitors5 
 




CYP3A4 + P-gp 
inhibitors 
 



















Nausea Dizziness, headache, 
abdominal pain, 
nausea, itch 









1Adapted from manufacturers’ SPCs and with reference to [89] ; consulting BNF and local guidelines also suggested 3 
2Strong inhibitors of both CYP3A4 and P-gp: ketoconazole, itraconazole, voriconazole, posaconazole, dronedarone, HIV protease inhibitors 4 
(increased anticoagulant effect) 5 
3Other inhibitors of CYP3A4 and P-gp (i.e. with less potent inhibition of one or both pathways): clarithromycin, erythromycin, fluconazole 6 
(increased anticoagulant effect) 7 
4CYP3A4 inducers: rifampicin, phenytoin, carbamazepine, phenobarbitone, St. John’s wort (reduced anticoagulant effect)  8 
5Strong P-gp inhibitors: as (2), also ciclosporin, tacrolimus and erythromycin (increased anticoagulant effect) 9 
6Other P-gp inhibitors: verapamil (note dose reduction for dabigatran), amiodarone, quinidine, clarithromycin, ticagrelor (increased 10 
anticoagulant effect) 11 
 18 
7P-gp inducers: rifampicin, phenytoin, carbamazepine, phenobarbitone, St. John’s wort (reduced anticoagulant effect)  1 
8Major warfarin interactions: allopurinol, azoles, omeprazole, amiodarone, tamoxifen, statins (esp. fluvastatin), fibrates, erythromycin, 2 
metronidazole (increased effect); phenobarbitone, primidone, carbamazepine, rifampicin, phenytoin, azathioprine, St. John’s wort (reduced 3 
effect); steroids, nevirapine, ritonavir (unpredictable effects); liver, broccoli, sprouts, leafy greens (high vitamin K content – reduced effect) 4 
 5 
 6 
Choosing between DOACs 7 
Some differences were observed in the performance of the DOACs in their phase three trials against 8 
warfarin. Dabigatran 150mg BD, edoxaban 60mg, and apixaban were superior for the prevention of 9 
stroke and systemic embolism, mainly driven by a reduced risk of intracerebral haemorrhage, whereas 10 
rivaroxaban was non-inferior. Only dabigatran 150mg BD was superior for prevention of ischaemic 11 
stroke. Apixaban, edoxaban and dabigatran 110mg BD were associated with a lower risk of major 12 
bleeding, and edoxaban 30mg with a lower risk of GI bleeding. Dabigatran 150mg BD and rivaroxaban 13 
had higher risks of gastrointestinal bleeding. Given the absence of head-to-head randomised 14 
controlled trials, attempts have been made to infer their relative efficacy through network meta-15 
analysis; that is, a systematic assessment of their performance against warfarin as a common 16 
comparator. In the largest analysis of this type, the authors concluded that apixaban offered the 17 
optimal balance of safety and efficacy, with dabigatran showing the greatest efficacy but a less 18 
favourable safety profile [90].  19 
Caution is needed in the interpretation of these results. Although the authors showed a lack of effect 20 
modification by age, gender balance or CHADS2, they could not control for other possible sources of 21 
confounding. For instance, the ROCKET-AF trial of rivaroxaban included a substantially higher-risk 22 
population with more co-morbidities than RE-LY or ARISTOTLE, not all of which are accounted for in 23 
the CHADS2 score. There is therefore still a need for high-quality RCT evidence, though large numbers 24 
would be needed to compare treatments likely to have similar effect sizes. Until such evidence is 25 
Box 1: Indications for VKAs over DOACs 
 Absolute 
o Prosthetic (mechanical) heart valve  
o Valvular atrial fibrillation (due to moderate or severe mitral 
stenosis, usually of rheumatic origin) 
o Severe renal impairment 
 
 Relative 
o Comorbid malignancy 
o Patient choice (e.g. if long-established on warfarin) 
o Extremes of body weight (pharmacokinetics/dosing of DOAC 
unclear) 
o Likelihood of poor compliance without monitoring blood tests 
 
 19 
available, we do not think there is sufficient evidence to make a general recommendation for a 1 
particular DOAC; rather, we suggest balancing the available evidence with patient characteristics and 2 
preferences in choosing an anticoagulant. For some patients, apixaban might be a reasonable default 3 
choice, especially those with impaired renal function. We would consider dabigatran for patients with 4 
high ischaemic stroke risk and low bleeding risk, but avoid it in patients with significant dyspepsia or 5 
previous major GI bleeding. For patients who prefer once-daily dosing, edoxaban and rivaroxaban may 6 
aid compliance. Interactions with other medication should be considered. We recommend the recent 7 
American College of Chest Physicians guidelines for further advice on anticoagulant selection [64]. 8 
Timing of anticoagulation 9 
The optimal timing to start anticoagulation after a cardioembolic stroke is unclear. Based on studies 10 
of heparin, very early (<48hrs) anticoagulation increases the risk of symptomatic intracranial 11 
haemorrhage without reducing the risk of early recurrence (7-14 days), morbidity or mortality [91]. 12 
Current practice is therefore to delay anticoagulation by up to fourteen days. As the risk of recurrence 13 
in this time is around 5%, many clinicians will anticoagulate earlier, according to the size of the infarct 14 
and presence of haemorrhagic transformation. The ‘1-3-6-12’ rule-of-thumb, based only on expert 15 
opinion, suggests anticoagulation on days 1, 3, 6 and 12 respectively after TIA, minor, moderate and 16 
large infarcts [92]. The lower risk of ICH with DOACs may facilitate earlier anticoagulation, and 17 
observational studies do suggest that the risk of symptomatic intracranial haemorrhage in patients 18 
treated with DOACs within the first five days of ischaemic stroke is low, as is the risk of new 19 
asymptomatic haemorrhagic transformation [93,94], at least in patients with small infarcts . Four large 20 
upcoming RCTs, OPTIMAS, TIMING, START and ELAN, will assess the benefit of early anticoagulation 21 
(<4 days) in patients with AF-related stroke, with OPTIMAS due to recruit ~3500 participants 22 
throughout the UK from early 2019 [95]. 23 
6. COMMON CHALLENGES DURING ANTICOAGULATION 24 
The main challenges encountered in patients established on oral anticoagulation for stroke prevention 25 
in atrial fibrillation comprise treatment failure – recurrent ischaemic stroke – and bleeding 26 
complications - most seriously, intracerebral haemorrhage (ICH). 27 
Management of recurrent ischaemic stroke 28 
In this event, the first priority is to determine the patient’s eligibility for hyperacute treatment. In 29 
patients taking warfarin, point-of-care INR testing provides an immediate answer: an INR of 1.7 or less 30 
does not contraindicate thrombolysis [96]. With DOACs, this is less straightforward. Although some 31 
standard laboratory clotting indices (particularly the APTT) may be influenced by DOACs, they are not 32 
 20 
reliable markers of the degree of anticoagulation. More valid assays, such as factor Xa levels (for 1 
apixaban, edoxaban and rivaroxaban) and dilute thrombin time (dabigatran), are not usually available 2 
quickly. In the absence of an assay result excluding a significant DOAC effect, US guidelines advise 3 
against thrombolysis unless it can be clearly established that the patient last took a DOAC more than 4 
48hrs ago and has normal renal function [27]. The European Society of Cardiology recommends also 5 
considering thrombolysis for patients who last took a DOAC between 24 and 48hrs ago, if renal 6 
function is normal and they are otherwise a good candidate [89]. In patients not meeting these criteria, 7 
proceeding directly to mechanical thrombectomy should be considered in patients with thrombus 8 
within the basilar artery or proximal middle cerebral artery. Successful thrombolysis has been 9 
reported after dabigatran reversal. For patients taking FXa inhibitors, a pathway using a rapid anti-Xa 10 
activity assay (RivLev) to guide thrombolysis in patients taking rivaroxaban has been tested 11 
successfully in a single centre [97]. Importantly, over half the patients included who would not have 12 
been eligible for thrombolysis based on last DOAC intake had a RivLev result compatible with 13 
thrombolysis [98].  We are introducing a similar pathway in our centre, and our practice in the absence 14 
of a FXa level reflects European guidelines.  15 
Poor compliance is the most obvious cause for treatment failure. In this case, the underlying reasons 16 
should be addressed, which may involve continuing the existing treatment with measures to improve 17 
compliance or choosing a new OAC more acceptable to the patient (for instance, a FXa inhibitor rather 18 
than dabigatran in patients with GI side-effects, a DOAC rather than warfarin in patients reluctant to 19 
undergo blood tests, or a once-daily rather than twice daily DOAC). If compliance is good, drug and 20 
dietary interactions should be considered. A few patients suffer a recurrent ischaemic stroke despite 21 
apparently therapeutic anticoagulation, perhaps due to an alternative mechanism such as 22 
atherosclerosis or small vessel occlusion. There is no accepted evidence-based strategy for such 23 
patients. Seeking any treatable alternative cause of stroke (e.g. carotid stenosis) or stroke “mimic” is 24 
essential. In those on warfarin, a switch to a DOAC might be recommended. Increasing the target INR 25 
instead is associated with a high risk of bleeding. In those on DOACs, an alternative DOAC (with a 26 
different mechanism of action or more frequent dosing) could be used, or a switch to warfarin could 27 
be made if closer monitoring is thought desirable. Adding an antiplatelet is not generally 28 
recommended (at least not long-term), as the concurrent use of aspirin with an anticoagulant was 29 
associated with increased bleeding but not a reduction in the risk of all-cause stroke and systemic 30 
embolism in the RE-LY [99] and SPORTIF [100] trials. 31 
Management of OAC-associated ICH 32 
 21 
The management of oral anticoagulant-associated ICH entails supportive care, rapid reduction of 1 
systolic blood pressure to <140mmHg [101], and reversal of anticoagulation. For patients taking 2 
warfarin, this is achieved with 5-10mg vitamin K intravenously, and replacement of the vitamin K-3 
dependent clotting factors (II, VII, IX and X) with four-factor prothrombin complex concentrate (e.g. 4 
Beriplex, Octaplex) in preference to fresh frozen plasma [102]. For patients taking DOACs, there is no 5 
role for vitamin K supplementation, as DOACs act downstream of the vitamin-K dependent portion of 6 
the clotting cascade. Four-factor prothrombin complex concentrate has been used off-label, and is 7 
recommended by European Heart Rhythm Association guidelines [89], but evidence for efficacy is 8 
limited. For dabigatran, a specific monoclonal antibody antidote, idarucizumab, is available, rapidly 9 
and safely normalising laboratory clotting indices and achieving normal intra-operative haemostasis 10 
in patients needing emergency surgery in an uncontrolled phase three study [103]. We recommend 11 
the immediate use of this agent where available in dabigatran-related intracerebral haemorrhage. A 12 
decoy protein reversal agent for FXa inhibitors, andexanet alfa, has been tested in a small clinical study 13 
[104] and has recently been licensed in the United States. It remains expensive and clinically unproven 14 
for FXa inhibitor-related ICH, with a potential procoagulant effect from binding tissue factor, which 15 
could account for an increased rate of thrombosis reported [103]. Thus, if available, adexanet alfa can 16 
be considered for FXa-associated intracerebral haemorrhage, ideally as part of a randomised 17 
controlled trial.  Nevertheless, even without the use of a reversal agent, the outcome in patients with 18 
DOAC-related ICH is no worse than that of patients with VKA-ICH in whom anticoagulation is reversed 19 
[105].  20 
Because of the early risk of haematoma expansion, anticoagulation is commonly withheld for at least 21 
two weeks after anticoagulant-related ICH even in patients with a strong indication (most often AF). 22 
After this, the decision whether to restart anticoagulation is challenging. A meta-analysis of 23 
observational studies found that resuming anticoagulation reduces the risk of ischaemic stroke 24 
without increasing the risk of haemorrhage [106], with a median time to resumption of 10 – 39 days. 25 
Nationwide observational data from Sweden also suggests benefit from resuming anticoagulation, 26 
estimating the optimal timing to be 7-8 weeks after ICH [107]. Although it is likely that these results 27 
are subject to bias, with lower-risk patients more likely to be selected for resumption of 28 
anticoagulation, this does suggest that at least some patients can safely resume anticoagulation. 29 
Several RCTs – including SoSTART, APACHE-AF and PRESTIGE-AF – will provide more definitive 30 
evidence, and an individual patient data meta-analysis is planned through the COCROACH 31 
collaboration. In the interim, we suggest a careful re-evaluation of the bleeding and stroke risks, 32 
including ICH location (as the recurrence risk of lobar haemorrhage is about four times greater than 33 
non-lobar haemorrhage [108]) and MR imaging markers of cerebral amyloid angiopathy [109], careful 34 
 22 
control of modifiable risk factors, and use of a DOAC in preference to warfarin. We strongly encourage 1 
randomisation of eligible patients into ongoing trials, but left atrial appendage occlusion may 2 
reasonably be considered if the risk of recurrent ICH is judged to be unacceptably high. 3 
 7. MANAGEMENT IN SPECIAL CIRCUMSTANCES 4 
When anticoagulation is contraindicated 5 
In reality, there is no agreement on what constitutes an absolute long-term “contraindication” to oral 6 
anticoagulation but, rather, a spectrum of risk which can change over time. As clinical data indicate 7 
that 90% of all cardiac thrombi in non-rheumatic AF originate from the left atrial appendage (LAA) 8 
[110], exclusion of the  left atrial appendage from the circulation offers an alternative strategy for 9 
stroke prevention in patients in whom OAC is thought to be unacceptably high-risk. Surgical excision 10 
of the LAA is undertaken in patients undergoing cardiac surgery (e.g. mitral valve or MAZE procedures) 11 
and is highly unlikely to be offered as an independent intervention purely to reduce stroke risk, 12 
whereas catheter-based left atrial appendage closure devices can achieve minimally invasive LAA 13 
occlusion (LAAO). 14 
The Boston Scientific Watchman is FDA approved. In two prospective RCTs comparing the Watchman 15 
to warfarin (PROTECT-AF [111] and PREVAIL [112]), LAAO was not, overall, inferior for the endpoint of 16 
ischaemic stroke and systemic embolism, although there was a higher rate of early, intervention-17 
related, complications including ischaemic stroke. Ischaemic events after the first 7 days were not 18 
significantly different, but rates of major bleeding and particularly haemorrhagic stroke, were 19 
significantly lower in the LAAO-managed groups. The overall findings persisted over 5-year follow-up, 20 
indicating that the devices are comparable to warfarin in reducing the rate of ischaemic stroke but 21 
with a lower risk of haemorrhage (particularly intracerebral haemorrhage) [113]. The European 22 
Society of Cardiology AF Management guidelines [8] recommend that LAAO be used in high-risk 23 
patients in whom warfarin is contra-indicated (IIb indication, level of evidence B). The recent American 24 
College of Chest Physicians guidelines also suggest LAAO in patients with a strong contraindication to 25 
oral anticoagulation [64].  26 
However, these LAAO trials were undertaken in predominantly intermediate risk patients 27 
(CHA2DS2VASc 1–2) and excluded patients in whom warfarin was contraindicated. The Watchman 28 
also requires short-term oral anticoagulation, and, based on currently-available data, long-term 29 
antiplatelet therapy. This appears anomalous to the clinical guideline recommendations: it seems 30 
unlikely that many patients with a true contraindication to long-term anticoagulation would tolerate 31 
short-term anticoagulation and long-term antiplatelet therapy [114]. Observational evidence suggests 32 
 23 
that dual antiplatelet therapy for three to six months in place of anticoagulation may be a safe 1 
alternative, even in patients with previous ICH [115,116]. However, given that long-term single 2 
antiplatelet therapy is still mandated, which arguably has a bleeding risk similar to DOAC therapy 3 
[117], it remains unclear whether LAAO offers a clear benefit over contemporary medical therapy. It 4 
should also be noted that incomplete LAA occlusion may increase thromboembolic risk and so 5 
mandate anticoagulation [114], and that the insertion procedure is not without risk (notably, a roughly 6 
3% risk across PREVAIL and PROTECT-AF of serious pericardial effusion requiring treatment). 7 
Therefore, though LAAO is supported by current international guidelines and is an option that should 8 
be discussed with the cardiologists, the key clinical trials have yet to be performed to demonstrate its 9 
efficacy and safety in moderate- and high-risk patients. 10 
There is also interest in whether electrophysiological ablation can reduce ischaemic stroke risk in AF. 11 
We believe this should be viewed as a potential adjunct to anticoagulation, not an alternative, not 12 
least due to the risk of AF recurrence [118]. Although there is observational evidence to suggest 13 
ablation may reduce stroke risk [119], the recent CABANA trial of ablation against medical therapy 14 
(both with anticoagulation) did not meet its primary end-point of a composite of death, disabling 15 
stroke, major bleeding and cardiac arrest in an intention-to-treat analysis [120]. While there was a 16 
high cross-over rate from ablation to medical treatment, and a positive result was obtained in a per 17 
protocol analysis, publication of the detailed results is awaited, and per protocol findings should be 18 
considered hypothesis-generating. 19 
Embolic Stroke of Undetermined Source 20 
20–25% of ischaemic strokes remain cryptogenic despite routine investigations, including non-21 
invasive monitoring. Many of these may be embolic, for instance from low-risk cardiac sources, aortic 22 
arch or non-occlusive carotid plaque, or covert paroxysmal AF [121]. It has been argued that 23 
anticoagulation in these patients might be more effective in reducing stroke risk than an antiplatelet. 24 
The concept of “embolic stroke of undetermined source” (ESUS) as a target for anticoagulation has 25 
been tested in three clinical trials. NAVIGATE ESUS was recently stopped early on the basis of a 26 
planned interim analysis showing an excess of bleeding with rivaroxaban 15mg OD compared to 27 
aspirin, and a low probability of a reduction in stroke risk [122]. RE-SPECT ESUS, with a similar design 28 
using dabigatran, is yet to finally report [123]; however, data presented in abstract form at the World 29 
Stroke Conference in October 2018 reported the rate of recurrent stroke (primary outcome) was 4.1% 30 
per year with dabigatran and 4.8% per year with aspirin (HR 0.85; P = 0.1). The rate of major bleeding 31 
was similar in both arms - 1.7% per year with dabigatran and 1.4% per year with aspirin. ATTICUS will 32 
 24 
test apixaban in a population enriched for probable cardioembolism, with radiological re-infarction at 1 
12 months as the primary end point [124].  2 
As well as the echocardiographic markers (left atrial dilation, spontaneous LAA echo contrast, reduced 3 
LAA flow velocity) used for patient selection in ATTICUS, ECG markers of left atrial function may have 4 
a role in identifying ESUS patients more likely to benefit from anticoagulation. For example, increased 5 
p-wave terminal force, defined as the amplitude of the terminal negative deflection of the p-wave in 6 
lead V1 multiplied by its duration, is a risk factor for cryptogenic or cardioembolic stroke, even in 7 
patients without AF [125]. This lends support to the concept of “left atrial cardiopathy” as an 8 
independent cause of cardioembolic stroke and a potential target for future anticoagulation trials  9 
[44]. However, in the absence of positive trial results, we recommend usual antiplatelet treatment 10 
combined with intensive investigation for established high-risk cardiac sources in patients with 11 
suspected but unproven cardioembolic stroke. 12 
Patients with Cardiovascular Comorbidities 13 
Whereas cardio-embolism is most effectively prevented by anticoagulation, atherosclerotic disease 14 
affecting the coronary, cervical or peripheral arteries is usually treated with an antiplatelet, based on 15 
the pathophysiological concept of the ‘red’, fibrin-rich thrombus forming under slow-flow conditions 16 
and the ‘white’, platelet-rich thrombus forming on ulcerated plaque. Arterial disease is common in AF 17 
patients, sometimes prompting dual therapy. Large registry studies indicate that combining warfarin 18 
and an antiplatelet clearly increases bleeding risk [126] without improving cardiovascular outcomes 19 
in patients with coronary or peripheral arterial disease [127,128]. Post-hoc analyses of ROCKET-AF 20 
suggest a similar pattern with rivaroxaban [129]. The distinction between anticoagulation- and 21 
antiplatelet-responsive thrombi is unlikely to be absolute – for instance, both warfarin and 22 
rivaroxaban have shown efficacy in place of an antiplatelet in treating coronary artery disease 23 
[130,131]. Reflecting European Heart Rhythm Association guidelines, in anticoagulated AF patients, 24 
we do not add an antiplatelet for secondary prevention in atherosclerotic disease. In patients with AF 25 
undergoing PCI, triple therapy with dual antiplatelets and a DOAC is generally recommended for 1 to 26 
6 months (based on an assessment of atherothrombotic and bleeding risk), then dual therapy to 27 
complete 12 months, then anticoagulation monotherapy. In patients with severe or symptomatic 28 
carotid stenosis, endarterectomy should be performed in preference to stenting, with the addition of 29 
aspirin immediately before surgery, and for ten days afterwards [89]. 30 
The findings of the COMPASS trial [131] raise a possible alternative approach to stroke prevention in 31 
AF patients with atherosclerotic comorbidities. The combination of rivaroxaban 2.5mg BD and aspirin 32 
improved cardiovascular outcomes, including ischaemic stroke risk, in a population with stable 33 
 25 
atherosclerotic cardiovascular disease compared to aspirin alone, whereas rivaroxaban 5mg BD alone 1 
did not. These results may also have implications for AF patients who suffer a recurrent ischaemic 2 
stroke despite therapeutic anticoagulation. However, both rivaroxaban doses used were low 3 
compared to that used for stroke prevention in AF, and very few patients with AF were included 4 
(392/27395). RCT evaluation of such an approach in AF patients with atherosclerotic comorbidities 5 
might be of interest. 6 
8. CONCLUSION 7 
As the commonest cardiac arrhythmia and main cause of cardioembolic stroke, a working knowledge 8 
of atrial fibrillation is essential for most practising neurologists and all stroke physicians. The diagnosis 9 
of AF offers an opportunity to greatly reduce the risk of ischaemic stroke through prompt 10 
anticoagulation. The now widely-available DOACs facilitate this, offering fewer practical difficulties 11 
and a lower risk of complications than warfarin. Many apparent contraindications to anticoagulation 12 
do not outweigh its benefits, but left atrial appendage occlusion might be a reasonable alternative in 13 
carefully-selected patient at unacceptably high risk of bleeding on long-term oral anticoagulation. In 14 
patients with cryptogenic stroke, intensive investigation for AF with prolonged ECG monitoring will 15 
diagnose a significant minority with AF, but the stroke risk associated with low-burden paroxysmal AF 16 
is uncertain. In the remainder of patients with suspected but unproven cardioembolism, there is 17 
currently no role for empirical anticoagulation, although further trials are ongoing. Advances in 18 
monitoring technology, the use of biomarkers to refine stroke and bleeding risk assessment, and the 19 
greater availability of DOAC reversal agents, are exciting prospects for improving the care of AF 20 
patients in the near future. 21 
 22 
 23 
Box 2: Key Points 
 Atrial fibrillation increases ischaemic stroke risk five-fold and justifies anticoagulation 
in the vast majority of patients, even those who are old, frail or have had falls. 
 DOACs are at least as effective as warfarin and offer a much lower risk of intracranial 
haemorrhage, so should be preferred for most patients. 
 The yield of investigation for AF after stroke is high, and will increase as advanced non-
invasive and implanted monitors become more widely available. 
 When anticoagulation fails and recurrent ischaemic stroke occurs, thrombolysis may 
be possible even in patients using DOACs. 
 Even after anticoagulant-related ICH, restarting anticoagulation might be beneficial, 
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FIGURE LEGENDS 9 
Figure 1: 10 
MR imaging showing patterns of acute infarction associated with cardioembolism.  11 
Top row, from left: diffusion-weighted imaging showing isolated cortical infarct, small wedge-shaped 12 
predominantly cortical infarct, and medium-sized cortico-subcortical infarct; T2 weighted imaging 13 
showing large wedge-shaped infarct with T2 hypointensity indicating haemorrhagic transformation. 14 
Bottom row, left to right: PCA territory infarction, scattered cortical and subcortical infarcts within 15 
right MCA territory, striatocapsular infarction with additional small right MCA territory infarcts 16 
(suggesting transient M1 occlusion then fragmentation and distal embolization of thrombus), 17 
scattered bihemispheric lesions.  18 
Figure 2:  19 
Patch and lead monitoring devices (left to right): e-Patch, Zio, CAM, R-test, Apoplex 20 
Figure 3:  21 
The Reveal-LINQ is a small implanted cardiac monitor, inserted subcutaneously in the precordium via 22 
a <1cm incision. 23 
Figure 4:  24 
Cerebral microhaemorrhages and intracerebral haemorrhage. Left to right: small left frontal cortical 25 
infarct demonstrated on DWI in a patient with atrial fibrillation; susceptibility-weighted imaging shows 26 
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